Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019079 (
hemoptysis
)
6,129
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
OBJECTIVE:
To identify risk factors influencing outcomes of bronchial arterial embolisation (BAE) in tuberculosis (TB) related
haemoptysis
.
METHODS:
A cohort of 207 patients underwent BAE for TB-related
haemoptysis
between March 2014 and March 2018. The clinical data were reviewed. Follow-up ranged from 24 to 1749 days.
RESULTS:
Immediate haemostasis rate was 94.2%; aggressive pleural thickening (PT) was found to be a risk factor for
haemoptysis
(
P
= 0.000, OR 22.52). Cumulative recurrence-free rates were respectively 98.5%, 94.8%, 88.7%, 79.9%, 68.5%, 65.7% and 62.7% for 1, 3, 6, 12, 24, 36 and 48 months. Respectively 8 and 15 patients recovered from pneumonectomy and re-BAE. However, five patients required a third BAE. The Cox regression analysis indicated that aggressive PT (
P
= 0.000), diabetes mellitus (DM) (
P
= 0.018) and pulmonary fungal infection (PFI) (
P
= 0.001) were independent risk factors for recurrence. The death rate following BAE was 9.2%; aggressive PT was a risk factor (
P
= 0.000, OR 8.14).
CONCLUSION:
BAE is effective for TB-related
haemoptysis
in most cases.
Aggressive
PT, DM and PFI are independent risk factors influencing the prognosis following BAE. PFI and DM should be well managed, while proper surgery should be considered for aggressive PT.
...
PMID:Effect of bronchial artery embolisation on the management of tuberculosis-related haemoptysis. 3193 10
<< Previous
1
2